In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on March, 16th 2020. Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2 in the community and within the hospital. Depending on the country, contact subjects considered to be at high or moderate risk of SARS-CoV-2 are, either isolated at home for a period of time defined by the health authorities or, on the contrary, continue their professional activity on the condition that they adopt measures to prevent transmission to those around them. In most European countries, healthcare workers adopt this second option. In all cases, it is most often recommended that contact persons monitor their state of health and communicate it to the persons dedicated to this action. Whether such subjects become spreaders of the virus is not known, nor is the proportion of viral spreader who will develop a symptomatic infection.
Procedures added by the research: Phone calls for collection of reported symptoms. Nasopharyngeal swabs for determination of the presence of SARS-CoV-2 detected by PCR. Blood sampling for determination of the presence of SARS-CoV-2 IgM or IgG. Saliva or blood sampling for whole exome sequencing of the subject.
Study Type
OBSERVATIONAL
Enrollment
324
Nasopharyngeal swabs
Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon
Besançon, France
Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin
Bordeaux, France
Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand
Clermont-Ferrand, France
Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne
Dijon, France
Centre d'investigation clinique 1406 CHU Grenoble
Grenoble, France
Centre d'Investigation Clinique 1403 -CHU Lille
Lille, France
Centre Investigation Clinique 1433 CHRU de NANCY
Nancy, France
Centre d'Investigation Clinique Hôpital Saint Louis
Paris, France
Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard
Paris, France
Centre Investigation Clinique 1417 Hôpital Cochin Bâtiment Lavoisier
Paris, France
...and 6 more locations
Time to SARS-CoV-2 nasopharyngeal excretion, from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.
PCR at day 0, day 3, day 5, day 7 and day 12 following the last high/moderate risk contact
Time frame: 12 days (+/-2)
Time to apparition of any symptom suggestive of SARS-CoV-2 from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.
Patient Reported Outcome assessed daily (fever \> 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...)
Time frame: 12 days (+/-2)
Factors associated with the time to SARS-CoV-2 nasopharyngeal excretion
nasopharyngeal excretion assessed by PCR at day 0, day 3, day 5, day 7 and day 12 following the last high/moderate risk contact
Time frame: 12 days (+/-2)
Factors associated with the time to apparition of any symptom suggestive of SARS-CoV-2 infection
Patient Reported Outcome assessed daily (fever \> 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...)
Time frame: 12 days (+/-2)
Proportion of contact subjects with apparition of any symptom suggestive of SARS-CoV-2 infection
Patient Reported Outcome assessed daily (fever \> 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...)
Time frame: 12 days (+/-2)
Proportion of contact subjects with positive serology defined as the presence of SARS-CoV-2 IgM or IgG at day 30 (+/-7) following last contact
ELISA, microneutralisation essay
Time frame: 30 days (+/-7)
Host genetic variants
Whole exome sequencing
Time frame: 1 day
The time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.
ELISA, microneutralisation essay
Time frame: 365 days (+/-30)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.